OBJECTIVES: To describe the clinical characteristics of patients with relapsing neuromyelitis optica (NMO) from a tertiary care center in Brazil and compare the groups with normal and abnormal brain magnetic resonance imaging (MRI). METHODS: Retrospective review of 41 patients followed at the Neuroimmunology Clinic of the Federal University of São Paulo, Brazil, from 1994 to 2007. RESULTS: All patients had relapsing-remitting optic-spinal disease, long extending spinal cord lesions, and brain MRI not meeting Barkhof criteria for multiple sclerosis (MS), thus fulfilling the 1999 and 2006 Wingerchuck criteria for NMO. Mean follow-up time was 52 months; mean age of onset was 32.6 years. The mean relapse rate (RR) and progression index (PI) were 1.0 and 0.9, respectively. Twenty-four patients had brain lesions not compatible with MS on MRI, and there were no statistical differences on PI and RR between patients who had brain lesions and patients who did not. Incomplete recovery, but not the type of first relapse, correlated with a worse prognosis. Seventeen patients were tested for NMO-IgG (anti-aquaporin-4 antibody) with 41% positivity. CONCLUSIONS: In this series, we did not find a statistical difference of disease progression between patients with and without brain lesions, suggesting that the presence of brain abnormalities is not a marker of disease severity.
OBJECTIVES: To describe the clinical characteristics of patients with relapsing neuromyelitis optica (NMO) from a tertiary care center in Brazil and compare the groups with normal and abnormal brain magnetic resonance imaging (MRI). METHODS: Retrospective review of 41 patients followed at the Neuroimmunology Clinic of the Federal University of São Paulo, Brazil, from 1994 to 2007. RESULTS: All patients had relapsing-remitting optic-spinal disease, long extending spinal cord lesions, and brain MRI not meeting Barkhof criteria for multiple sclerosis (MS), thus fulfilling the 1999 and 2006 Wingerchuck criteria for NMO. Mean follow-up time was 52 months; mean age of onset was 32.6 years. The mean relapse rate (RR) and progression index (PI) were 1.0 and 0.9, respectively. Twenty-four patients had brain lesions not compatible with MS on MRI, and there were no statistical differences on PI and RR between patients who had brain lesions and patients who did not. Incomplete recovery, but not the type of first relapse, correlated with a worse prognosis. Seventeen patients were tested for NMO-IgG (anti-aquaporin-4 antibody) with 41% positivity. CONCLUSIONS: In this series, we did not find a statistical difference of disease progression between patients with and without brain lesions, suggesting that the presence of brain abnormalities is not a marker of disease severity.
Authors: Amy M L Quek; Andrew McKeon; Vanda A Lennon; Jayawant N Mandrekar; Raffaele Iorio; Yujuan Jiao; Chiara Costanzi; Brian G Weinshenker; Dean M Wingerchuk; Claudia F Lucchinetti; Elizabeth A Shuster; Sean J Pittock Journal: Arch Neurol Date: 2012-08
Authors: Yujuan Jiao; James P Fryer; Vanda A Lennon; Sarah M Jenkins; Amy M L Quek; Carin Y Smith; Andrew McKeon; Chiara Costanzi; Raffaele Iorio; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Claudia F Lucchinetti; Sean J Pittock Journal: Neurology Date: 2013-08-30 Impact factor: 9.910
Authors: J Kuchling; T Sinnecker; I Bozin; J Dörr; V I Madai; J Sobesky; T Niendorf; F Paul; J Wuerfel Journal: Nervenarzt Date: 2014-04 Impact factor: 1.214
Authors: Sven Jarius; Klemens Ruprecht; Brigitte Wildemann; Tania Kuempfel; Marius Ringelstein; Christian Geis; Ingo Kleiter; Christoph Kleinschnitz; Achim Berthele; Johannes Brettschneider; Kerstin Hellwig; Bernhard Hemmer; Ralf A Linker; Florian Lauda; Christoph A Mayer; Hayrettin Tumani; Arthur Melms; Corinna Trebst; Martin Stangel; Martin Marziniak; Frank Hoffmann; Sven Schippling; Jürgen H Faiss; Oliver Neuhaus; Barbara Ettrich; Christian Zentner; Kersten Guthke; Ulrich Hofstadt-van Oy; Reinhard Reuss; Hannah Pellkofer; Ulf Ziemann; Peter Kern; Klaus P Wandinger; Florian Then Bergh; Tobias Boettcher; Stefan Langel; Martin Liebetrau; Paulus S Rommer; Sabine Niehaus; Christoph Münch; Alexander Winkelmann; Uwe K Zettl U; Imke Metz; Christian Veauthier; Jörn P Sieb; Christian Wilke; Hans P Hartung; Orhan Aktas; Friedemann Paul Journal: J Neuroinflammation Date: 2012-01-19 Impact factor: 8.322
Authors: L Pandit; N Asgari; M Apiwattanakul; J Palace; F Paul; M I Leite; I Kleiter; T Chitnis Journal: Mult Scler Date: 2015-04-28 Impact factor: 6.312
Authors: Regina Maria Papais-Alvarenga; Claudia Cristina Ferreira Vasconcelos; Adriana Carra; Ibis Soto de Castillo; Sara Florentin; Fernando Hamuy Diaz de Bedoya; Raul Mandler; Luiza Campanella de Siervi; Maria Lúcia Vellutini Pimentel; Marina Papais Alvarenga; Marcos Papais Alvarenga; Anderson Kuntz Grzesiuk; Ana Beatriz Calmon Gama Pereira; Antonio Pereira Gomes Neto; Carolina Velasquez; Carlos Soublette; Cynthia Veronica Fleitas; Denise Sisteroli Diniz; Elizabeth Armas; Elizabeth Batista; Freda Hernandez; Fernanda Ferreira Chaves da Costa Pereira; Heloise Helena Siqueira; Hideraldo Cabeça; Jose Sanchez; Joseph Bruno Bidin Brooks; Marcus Vinicius Gonçalves; Maria Cristina Del Negro Barroso; Maria Elena Ravelo; Maria Carlota Castillo; Maria Lúcia Brito Ferreira; Maria Sheila Guimarães Rocha; Monica Koncke Fiuza Parolin; Omaira Molina; Patricia Beatriz Christino Marinho; Paulo Pereira Christo; Renata Brant de Souza; Silvio Pessanha Neto; Solange Maria das Graças Camargo; Suzana Costa Machado; Vanderson Carvalho Neri; Yara Dadalti Fragoso; Helcio Alvarenga; Luiz Claudio Santos Thuler Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240
Authors: Nishita Singh; Rohit Bhatia; Prerna Bali; V Sreenivas; M V Padma; Vinay Goyal; Rohit Saxena; Deepa Dash; Ajay Garg; S Leve Joseph Journal: Ann Indian Acad Neurol Date: 2020-01-06 Impact factor: 1.383